Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Demographic and baseline data in the randomised set.

From: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

 

IM Group

N= 374

SC Group

N= 378

Age at vaccination, months ± SD

13.8 ± 1.7

13.7 ± 1.6

Male, n (%)

206 (55.1)

210 (55.6)

Weight, kg ± SD

10.1 ± 1.2

10.2 ± 1.3

Height, cm ± SD

77.2 ± 3.6

77.4 ± 3.4

Seronegative, n (%)1

  

   Measles (<255 mIU/ml)

364 (97.3)

371 (98.1)

   Mumps (<10 ELISA Ab units/ml)

364 (97.3)

370 (97.9)

   Rubella (<10 IU/ml)

335 (89.6)

324 (85.7)

   Varicella (<1.25 gpELISA units/ml)

352 (94.1)

353 (93.4)

  1. (IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route).
  2. 1 It is not possible to calculate the seropositive rates directly from these data because of the missing values; overall 5 (0.7%) subjects were seropositive at baseline for measles, 11 (1.5%) for mumps, 81 (10.8%) for rubella and 37 (4.9%) for varicella
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us